Personalis, Inc.
PSNLNasdaq
$15.39
↓ -1.2%Jul 17 close · end-of-day
Price
1Y↑ +140.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.6B
Enterprise Value
$1.4B
P/E
—
P/S
24.9
P/B
6.3
EV/EBITDA
—
PEG
—
FCF Yield
-5.3%
Dividend Yield
—
Revenue (TTM)
$64.5M
Net Income (TTM)
-$95.6M
Free Cash Flow (TTM)
-$84.6M
Gross Margin
—
Operating Margin
-158.9%
Net Margin
-148.1%
ROE
-37.5%
ROIC
-375.9%
Debt / Equity
—
Net Cash
$233.2M
Return 1Y
+137.5%
Company profile
Personalis, Inc. operates as a cancer genomics company worldwide. It provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection.
- CEO
- John S. West
- Sector
- Services
- Industry
- Healthcare
- Employees
- 400
- Headquarters
- California
- Website
- personalis.com
Management & directors
- Chen RichardCHIEF MEDICAL OFFICER AND EVP
- Hall Christopher MChief Executive Officer
- Tachibana AaronCFO AND COO
- Moore Stephen MichaelSVP and Chief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
PSNL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$15.5M↓ -24.9%
Diluted EPS-$0.29↑ +61.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $78.6M | $85.5M | $65.0M | $73.5M | $84.6M | $69.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$42.1M | -$65.4M | -$115.5M | -$109.9M | -$68.3M | -$88.1M |
| Net income | -$41.3M | -$65.2M | -$113.3M | -$108.3M | -$81.3M | -$81.3M |
| Diluted EPS | -$1.20 | -$1.49 | -$2.48 | -$2.25 | -$1.37 | -$0.91 |
| Operating cash flow | -$42.7M | -$70.8M | -$70.2M | -$56.3M | -$45.1M | -$74.9M |
| Free cash flow | -$45.9M | -$81.9M | -$120.1M | -$67.2M | -$46.8M | -$79.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -53.6% | -76.4% | -177.6% | -149.6% | -80.7% | -126.4% |
| Net margin | -52.5% | -76.3% | -174.2% | -147.4% | -96.1% | -116.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.6M | $25.7M | $16.8M | $20.6M | $17.2M | $14.5M | $17.3M | $15.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.9M | -$14.4M | -$18.1M | -$17.7M | -$21.8M | -$23.3M | -$25.3M | -$32.2M |
| Net income | -$12.8M | -$39.1M | -$16.4M | -$15.8M | -$20.1M | -$21.7M | -$23.8M | -$30.0M |
| Diluted EPS | -$0.24 | -$0.64 | -$0.23 | -$0.18 | -$0.23 | -$0.24 | -$0.26 | -$0.29 |
| Operating cash flow | -$10.7M | -$6.2M | -$7.8M | -$18.0M | -$12.9M | -$21.8M | -$22.2M | -$22.5M |
| Free cash flow | -$10.7M | -$6.4M | -$9.0M | -$20.5M | -$13.2M | -$23.4M | -$22.3M | -$25.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -74.8% | -55.9% | -107.8% | -85.9% | -126.7% | -160.7% | -145.7% | -207.9% |
| Net margin | -56.7% | -152.0% | -97.8% | -76.4% | -116.6% | -149.4% | -137.3% | -194.1% |
Company news
Jul 20, 2026
- 39m agoTempus AI Buys Personalis in $1.7 Billion Precision Oncology Dealfinance.yahoo.com
- 1h agoTempus AI Scoops Up Personalis For $1.5 Billion; But Shares Divefinance.yahoo.com
- 1h agoTEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Dealstocktwits.com
- 2h agoTempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sinkfinance.yahoo.com
- 2h agoSector Update: Healthcare Stocks Fall Late Afternoonfinance.yahoo.com
- 2h agoTempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peersfinance.yahoo.com
- 5h agoCathie Wood Dumps $39 Million Worth of AMD Stockfinance.yahoo.com
- 5h agoTempus AI Bets on MRD Testing Growth With Personalis Acquisitionmarketbeat.com
- 6h agoTempus AI to acquire cancer-monitoring firm Personalis for $1.5Bproactiveinvestors.com
- 6h agoTEM’s Deal To Acquire PSNL Opens Door For $20B Cancer Market Opportunity – Retail Awaits To See Executionstocktwits.com
- 6h agoTempus to buy cancer test-maker Personalis for $1.5Bmedtechdive.com
- 8h agoTempus AI to Acquire Personalis in $1.5 Billion Dealfinance.yahoo.com
- 9h agoTempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platformfinance.yahoo.com
- 9h agoDow drops 300 points as chip rally fades ahead of Big Tech earningsproactiveinvestors.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Chen Richard· President and CMO | Sale | 100,000 | $15.15 | $1.5M | filing |
| 2026-07-15 | Chen Richard· President and CMO | Option exercise | 100,000 | $2.44 | $244,000.00 | filing |
| 2026-07-09 | Hall Christopher M· Chief Executive Officer | Sale | 100,000 | $15.08 | $1.5M | filing |
| 2026-07-09 | Hall Christopher M· Chief Executive Officer | Option exercise | 100,000 | $1.61 | $161,000.00 | filing |
| 2026-06-29 | Tachibana Aaron· CFO AND COO | Sale | 4,982 | $14.00 | $69,748.00 | filing |
| 2026-06-29 | Tachibana Aaron· CFO AND COO | Option exercise | 4,982 | $5.32 | $26,504.24 | filing |
| 2026-06-26 | Hall Christopher M· Chief Executive Officer | Sale | 100,000 | $13.15 | $1.3M | filing |
| 2026-06-26 | Tachibana Aaron· CFO AND COO | Sale | 51,251 | $13.18 | $675,488.18 | filing |
| 2026-06-26 | Tachibana Aaron· CFO AND COO | Option exercise | 28,832 | $9.16 | $264,101.12 | filing |
| 2026-06-26 | Hall Christopher M· Chief Executive Officer | Option exercise | 100,000 | $1.61 | $161,000.00 | filing |
| 2026-06-26 | Tachibana Aaron· CFO AND COO | Option exercise | 22,419 | $5.32 | $119,269.08 | filing |
| 2026-06-04 | Tachibana Aaron· CFO AND COO | Sale | 40,000 | $12.01 | $480,400.00 | filing |
| 2026-06-04 | Tachibana Aaron· CFO AND COO | Option exercise | 40,000 | $9.16 | $366,400.00 | filing |
| 2026-05-29 | Hall Christopher M· Chief Executive Officer | Sale | 80,091 | $11.02 | $882,602.82 | filing |
| 2026-05-29 | Tachibana Aaron· CFO AND COO | Sale | 38,799 | $11.58 | $449,292.42 | filing |
| 2026-05-29 | Tachibana Aaron· CFO AND COO | Option exercise | 38,799 | $9.16 | $355,398.84 | filing |
| 2026-05-29 | Hall Christopher M· Chief Executive Officer | Option exercise | 80,091 | $1.61 | $128,946.51 | filing |
| 2026-05-28 | Hall Christopher M· Chief Executive Officer | Sale | 19,909 | $11.02 | $219,397.18 | filing |
| 2026-05-28 | Hall Christopher M· Chief Executive Officer | Option exercise | 19,909 | $1.61 | $32,053.49 | filing |
| 2026-05-12 | EASTHAM KARIN | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-12 | BOWMAN A BLAINE | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-12 | WIDDER KENNETH J | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-12 | Shoff Lonnie | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-12 | Bloom Olivia Kyusuk | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-12 | MYERS WOODROW A JR | Award | 6,250 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.